Semantic Scholar uses AI to extract papers important to this topic.
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with… Expand Background:Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1… Expand PHSCN peptide (licensed as ATN-161) is an effective α5β1 integrin inhibitor that has advanced to phase II clinical trials to… Expand BackgroundAcquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent… Expand ABSTRACT Hydroxychloroquine (HCQ) inhibits autophagy and therefore can sensitize some cancer cells to chemotherapy, but the high… Expand BACKGROUND
Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor… Expand BACKGROUND
Despite improvement with intensive multi-agent chemotherapy, 2-year progression-free survival (PFS) rates for adults… Expand Stealth liposomes form an important subset of liposomes, demonstrating prolonged circulation half-life and improved safety in… Expand BackgroundPlatinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This… Expand 5006 Background: Bevacizumab (BV), a recombinant, humanized monoclonal antibody directed against vascular endothelial growth… Expand